Cwm LLC Has $61,000 Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Key Points

• Cwm LLC significantly reduced its holdings in Establishment Labs Holdings Inc. by 97.9%, selling 69,149 shares and retaining only 1,496 shares valued at $61,000.
• Institutional investors now own 72.91% of Establishment Labs' stock, with several funds increasing their positions during the fourth quarter.
• Analysts have a consensus target price of $54.83 for Establishment Labs, with ratings ranging from hold to buy by various brokerages.

CWM LLC lessened its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 97.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,496 shares of the company's stock after selling 69,149 shares during the period. CWM LLC's holdings in Establishment Labs were worth $61,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ESTA. Brown Advisory Inc. boosted its stake in shares of Establishment Labs by 23.1% during the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors boosted its stake in shares of Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares during the period. Findell Capital Management LLC boosted its stake in Establishment Labs by 28.5% in the 4th quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock valued at $62,032,000 after purchasing an additional 298,380 shares during the period. Bamco Inc. NY boosted its stake in Establishment Labs by 53.8% in the 4th quarter. Bamco Inc. NY now owns 752,886 shares of the company's stock valued at $34,685,000 after purchasing an additional 263,500 shares during the period. Finally, Millennium Management LLC boosted its stake in Establishment Labs by 96.9% in the 4th quarter. Millennium Management LLC now owns 711,691 shares of the company's stock valued at $32,788,000 after purchasing an additional 350,213 shares during the period. Institutional investors own 72.91% of the company's stock.

Establishment Labs Price Performance

Shares of Establishment Labs stock traded up $1.31 during trading on Tuesday, reaching $44.03. 267,314 shares of the company's stock were exchanged, compared to its average volume of 525,545. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $50.85. The company has a market cap of $1.27 billion, a P/E ratio of -14.20 and a beta of 0.83. The firm's 50-day moving average price is $40.53 and its 200 day moving average price is $36.89.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The company had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the previous year, the firm earned ($0.58) EPS. Establishment Labs's revenue was up 11.3% on a year-over-year basis. As a group, research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. BTIG Research assumed coverage on Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 price target for the company. Citigroup upped their target price on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Needham & Company LLC reiterated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. Mizuho upped their target price on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Finally, Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Establishment Labs currently has an average rating of "Moderate Buy" and a consensus target price of $54.83.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.